Navigation Links
Clarient to Commercialize Novel Breast Cancer Profile
Date:1/9/2008

Clarient Insight(TM) Dx Breast Cancer Profile Represents First Molecular

Test Applicable to All Stages of Operable Breast Cancer

ALISO VIEJO, Calif., Jan. 9 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will commercialize a novel breast cancer test, the first molecular test available that is applicable to all stages of operable breast cancer, including lymph node-positive patients. The new offering, called Clarient Insight(TM) Dx Breast Cancer Profile, will be sold by Clarient through an exclusive license agreement with Prediction Sciences, a La Jolla, CA-based company that develops high-value molecular diagnostics for disease detection, prognosis and selection of appropriate therapy.

Clarient's Insight Dx Breast Cancer Profile is a series of molecular assays that, when combined using Prediction Sciences' proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy. The profile could allow patients to avoid the toxic effects of unnecessary chemotherapy, thereby reducing the overall cost of care. The availability of the test through Clarient reflects the healthcare industry's move toward personalized medicine that helps physicians understand the unique aspects of a patient's disease in order to develop more effective treatment plans. Leading oncology organizations have recommended adopting this type of test since a large percentage of women who undergo chemotherapy have little chance of benefiting from the toxic treatment. According to industry analy
'/>"/>

SOURCE Clarient
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
3. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
4. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
9. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
10. First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
11. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Scientists at USC have developed a new microscopy ... in living animals at higher-than-ever resolution. , Dubbed ... allows imaging resolutions that are an order of ... insights into the behavior of biomolecules at the ... Sept. 18 by Nature Communications , the ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/18/2014)... New York, NY (PRWEB) September 18, 2014 ... has completed negotiations with Salem Realty Group and has ... and development space within the Salem Executive Complex adjacent ... cutting ceremony was held on Friday September 5th. Whitehouse ... to refit the entire space specifically for package testing. ...
(Date:9/17/2014)... Sept. 17, 2014 The global consumption of squalene ... Squalene is a natural skin-identical chemical that finds applications in ... food supplements, pharmaceuticals, and in other applications like high grade ... has a few major players and is regionally segregated. Sophim ... Liver Oil Co. Ltd. ( Japan ), SeaDragon ...
Breaking Biology Technology:Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... Third Quarter Highlights Recognized ... from Department of Defense (DoD) for nerve agent medical countermeasure ... profit split on worldwide sales of ST-246 and related products ... Completed 1500L commercial scale-up and first cGMP manufacturing run ...
... 8, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... today announced financial results for the third quarter of 2011. ... a net loss of $4.6 million, or $0.10 per share, ... $0.31 per share, for the third quarter of 2010. As ...
... for data-intensive biomedical and genetic research -- is ... team of researchers including Anton Nekrutenko, an associate ... State University; Kateryna Makova, an associate professor of ... Emory University, developed the new technology, which will ...
Cached Biology Technology:PharmAthene Reports Third Quarter 2011 Financial and Operating Results 2PharmAthene Reports Third Quarter 2011 Financial and Operating Results 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 4PharmAthene Reports Third Quarter 2011 Financial and Operating Results 5PharmAthene Reports Third Quarter 2011 Financial and Operating Results 6PharmAthene Reports Third Quarter 2011 Financial and Operating Results 7PharmAthene Reports Third Quarter 2011 Financial and Operating Results 8Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3
(Date:9/17/2014)... Informatics at IMIM (Hospital del Mar Medical Research Institute) ... recently published a study in eLife showing ... in the evolution of new proteins, some of which ... Ribosomes produce proteins from the instructions found in an ... is RNA containing information for the synthesis of proteins, ...
(Date:9/17/2014)... Mich. Mutations in the human retinoblastoma protein gene ... State University scientists have turned to fruit fly eyes ... , In a paper featured on the cover ... Biological Chemistry , Michigan State University researchers provide the ... to those present in the human cancer gene, said ...
(Date:9/17/2014)... decades of decline, grasses have returned to some once-denuded ... marsh in those places seems healthy again, but a ... the marsh coastal protection remains diminished. , ... hasn,t come back," said ecologist Mark Bertness, professor of ... in the journal Biological Conservation . "The metric ...
Breaking Biology News(10 mins):Parts of genome without a known function may play a key role in the birth of new proteins 2Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... In order for a gene to create a protein, ... as messenger RNA. These RNA molecules are the instruction manuals ... how to build a protein. A few years ago, scientists ... metabolic products (metabolites) can bind to. In doing so, they ...
... New drugs that are helping fight a multi-front war on ... of Georgia researchers said. Cancer and cardiovascular disease, both ... shock protein 90 inhibitors as a treatment could become additional ... Biology Center. "I think hsp90 inhibitors may be some ...
... David L. Rimoin, MD, PhD, FACMG of Cedars-Sinai ... College of Medical Genetics Foundation (ACMGF) second annual Lifetime ... Dr. Rimoin was recognized for his decades of contributions ... and heritable disorders of connective tissue, and for helping ...
Cached Biology News:Genes under control 2New cancer therapy may fight cardiovascular disease 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 3
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
... The Fujifilm Life Science LAS-3000 ... technology with a simplified user interface, ... a wide range of modularities. The ... applications, and the perfect standard system ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: